T1	p 30 43	high risk for
T2	p 94 123	metastatic breast cancer with
T3	p 286 301	complications (
T4	p 401 449	patients with metastatic breast cancer ( MBC ) .
T5	p 630 637	MBC ( n
T6	p 644 647	) (
T7	p 656 658	et
T8	p 777 786	ie , > or
T9	p 865 887	documented infection .
T10	p 1254 1270	poor performance
T11	p 1421 1426	age .
T12	p 1443 1453	score from
T13	p 1459 1465	=25 to
T14	p 1593 1601	Patients
T15	p 1607 1608	a
T16	p 1825 1843	colony stimulating
T17	p 1863 1868	those
T18	i 124 172	doxorubicin or pegylated liposomal doxorubicin :
T19	i 305 306	)
T20	i 314 396	chemotherapy with doxorubicin ( DOX ) or a pegylated liposomal formulation ( PLD )
T21	i 524 527	DOX
T22	i 540 543	2 )
T23	i 552 571	weeks ) or PLD ( 50
T24	i 579 582	2 )
T25	i 765 776	) cells/L (
T26	i 787 796	=grade II
T27	i 1133 1145	risk scoring
T28	i 1327 1334	cells/L
T29	i 1378 1407	chemotherapy , DOX versus PLD
T30	i 1773 1805	targeting preventative therapies
T31	i 1808 1859	eg , granulocyte colony stimulating factor or PLD )
T32	i 1908 1910	NC
T33	i 1918 1952	anthracycline-based chemotherapy .
T34	o 44 69	neutropenic complications
T35	o 274 299	neutropenic complications
T36	o 720 739	absolute neutrophil
T37	o 823 857	febrile neutropenia or neutropenia
T38	o 1259 1299	performance status , absolute neutrophil
T39	o 1429 1448	precycle risk score
T40	o 1541 1552	sensitivity
T41	o 1568 1579	specificity
T42	o 1897 1907	experience